Format

Send to

Choose Destination
Vaccine. 2016 Mar 18;34(13):1566-1574. doi: 10.1016/j.vaccine.2016.02.013. Epub 2016 Feb 11.

Immunogenicity of dimorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice.

Author information

1
Department of Biochemistry, University of Lausanne, Ch des Boveresses 155, Epalinges, Switzerland(1). Electronic address: balamsira@yahoo.fr.
2
Pasteur Institut, Paris, France. Electronic address: ajafarshad@gmail.com.
3
Department of Biochemistry, University of Lausanne, Ch des Boveresses 155, Epalinges, Switzerland(1). Electronic address: Ekaterini.Servi@unil.ch.
4
Department of Biochemistry, University of Lausanne, Ch des Boveresses 155, Epalinges, Switzerland(1). Electronic address: geraldine.frank@unil.ch.
5
IDRI, Seattle, USA. Electronic address: Steven.Reed@idri.org.
6
Department of Biochemistry, University of Lausanne, Ch des Boveresses 155, Epalinges, Switzerland(1). Electronic address: pinkr@mail.com.
7
Pasteur Institut, Paris, France. Electronic address: druilhe@vac4all.org.
8
Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. Electronic address: francois.spertini@chuv.ch.
9
Department of Biochemistry, University of Lausanne, Ch des Boveresses 155, Epalinges, Switzerland(1). Electronic address: giampietro.corradin@unil.ch.

Abstract

BACKGROUND:

Plasmodium falciparum MSP2 is a blood stage protein that is associated with protection against malaria. It was shown that the MSP2 dimorphic (D) and constant (C) regions were well recognized by immune human antibodies, and were characterized by major conserved epitopes in different endemic areas and age groups. These Abs recognized merozoite-derived proteins in WB and IFA. Here, the goal was to determine in mice the immunogenicity of the two allelic MSP2 D and C domains formulated with different adjuvants, for their possible use in future clinical studies.

METHOD:

Female A/J, C3H, and ICR mice were immunized subcutaneously 3 times at 3-week interval with a mixture of allelic and conserved MSP2 long synthetic peptides formulated with different adjuvants. One week after the third injection, sera from each group were obtained and stored at -20°C for subsequent testing.

RESULTS:

Both domains of the two MSP2 families are immunogenic and the fine specificity and intensity of the Ab responses are dependent on mouse strains and adjuvants. The major epitopes were restricted to the 20-mer peptide sequences comprising the last 8aa of D and first 12aa of C of the two allelic families and the first 20aa of the C region, this for most strains and adjuvants. Strong immune responses were associated with GLA-SE adjuvant and its combination with other TLR agonists (CpG or GDQ) compared to alhydrogel and Montanide. Further, the elicited Abs were also capable of recognizing Plasmodium-derived MSP2 and inhibiting parasite growth in ADCI.

CONCLUSION:

The data provide a valuable opportunity to evaluate in mice different adjuvant and antigen formulations of a candidate vaccine containing both MSP2 D and C fragments. The formulations with GLA-SE seem to be a promising option to be compared with the alhydrogel one in human clinical trials.

KEYWORDS:

Adjuvant; Constant region; Dimorphic region; Immunogenicity; MSP2; P. falciparum

PMID:
26874325
DOI:
10.1016/j.vaccine.2016.02.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center